Ocular Therapeutix (OCUL) Misses Q2 EPS by 12c

Ocular Therapeutix (NASDAQ: OCUL) reported Q2 EPS of ($0.45), $0.12 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $459 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Boston Omaha Corporation (BOC) Misses Q2 EPS by 2c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c